Drug search by name

Eculizumab Intravenous and Thrombotic microangiopathy

Result of checking the interaction of drug Eculizumab Intravenous and disease Thrombotic microangiopathy for safety when used together.

Check result:

Eculizumab Intravenous <> Thrombotic microangiopathy

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Thrombotic microangiopathy (TMA) complications have occurred after treatment discontinuation or after a missed dose of eculizumab. It is recommended to monitor patients with atypical hemolytic uremic syndrome for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. If TMA complications occur after eculizumab discontinuation, consider reinstitution of treatment, plasma therapy or appropriate organ-specific supportive measures.

Eculizumab Intravenous

Generic Name: eculizumab

Brand Name: Soliris

Synonyms: Eculizumab

What is Eculizumab Intravenous?